The prognostic value of serum β 2 microglobulin compared with other presentation features in myelomatosis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1985-07

AUTHORS

J Cuzick, E H Cooper, I C MacLennan

ABSTRACT

The levels of serum beta 2 microglobulin, blood urea concentration, serum creatinine, haemoglobin and performance status have been measured in 476 patients in the Medical Research Council's 4th trial for myelomatosis. Levels of serum beta 2 microglobulin were also subsequently measured in 208 patients who achieved a stable "plateau" condition. Serum beta 2 microglobulin levels, uncorrected for serum creatinine, were found to be the single most powerful prognostic variable available at presentation. Multivariate analysis showed that only the addition of haemoglobin levels could improve upon this and the improvement, though statistically significant (P = 0.006), appeared to be of much less clinical value. The prognostic value of serum beta 2 microglobulin at plateau appeared to be equally large for a given difference in value, but the variability between patients was much less at that time. Serum beta 2 microglobulin would appear to be a key measurement for assessing the prognosis and response to treatment in patients with myelomatosis. More... »

PAGES

1-6

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.1985.140

DOI

http://dx.doi.org/10.1038/bjc.1985.140

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051235803

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/3893505


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Creatinine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemoglobins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "beta 2-Microglobulin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "familyName": "Cuzick", 
        "givenName": "J", 
        "type": "Person"
      }, 
      {
        "familyName": "Cooper", 
        "givenName": "E H", 
        "type": "Person"
      }, 
      {
        "familyName": "MacLennan", 
        "givenName": "I C", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1980.273", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030704342", 
          "https://doi.org/10.1038/bjc.1980.273"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1983.13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030167230", 
          "https://doi.org/10.1038/bjc.1983.13"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1985-07", 
    "datePublishedReg": "1985-07-01", 
    "description": "The levels of serum beta 2 microglobulin, blood urea concentration, serum creatinine, haemoglobin and performance status have been measured in 476 patients in the Medical Research Council's 4th trial for myelomatosis. Levels of serum beta 2 microglobulin were also subsequently measured in 208 patients who achieved a stable \"plateau\" condition. Serum beta 2 microglobulin levels, uncorrected for serum creatinine, were found to be the single most powerful prognostic variable available at presentation. Multivariate analysis showed that only the addition of haemoglobin levels could improve upon this and the improvement, though statistically significant (P = 0.006), appeared to be of much less clinical value. The prognostic value of serum beta 2 microglobulin at plateau appeared to be equally large for a given difference in value, but the variability between patients was much less at that time. Serum beta 2 microglobulin would appear to be a key measurement for assessing the prognosis and response to treatment in patients with myelomatosis.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bjc.1985.140", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "52"
      }
    ], 
    "keywords": [
      "serum beta 2 microglobulin", 
      "beta 2 microglobulin", 
      "serum creatinine", 
      "prognostic value", 
      "powerful prognostic variable", 
      "Medical Research Council", 
      "blood urea concentration", 
      "microglobulin levels", 
      "performance status", 
      "hemoglobin levels", 
      "prognostic variables", 
      "clinical value", 
      "patients", 
      "multivariate analysis", 
      "microglobulin", 
      "myelomatosis", 
      "creatinine", 
      "presentation features", 
      "prognosis", 
      "levels", 
      "urea concentration", 
      "trials", 
      "serum", 
      "hemoglobin", 
      "treatment", 
      "presentation", 
      "status", 
      "response", 
      "differences", 
      "Research Council", 
      "improvement", 
      "values", 
      "concentration", 
      "addition", 
      "variables", 
      "time", 
      "plateau", 
      "variability", 
      "features", 
      "analysis", 
      "key measurements", 
      "conditions", 
      "measurements", 
      "Council"
    ], 
    "name": "The prognostic value of serum \u03b2 2 microglobulin compared with other presentation features in myelomatosis", 
    "pagination": "1-6", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051235803"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.1985.140"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "3893505"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.1985.140", 
      "https://app.dimensions.ai/details/publication/pub.1051235803"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_214.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bjc.1985.140"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1985.140'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1985.140'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1985.140'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1985.140'


 

This table displays all metadata directly associated to this object as RDF triples.

155 TRIPLES      22 PREDICATES      82 URIs      72 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.1985.140 schema:about N2c54e2b4d09c4dbaa615f6f0fc8278a6
2 N33d21185bd9d468990091091ed07b621
3 N4ed8fabc836343a39a4521fe04762dca
4 N7bce4d624071402a8b996eb2adf92065
5 N874585776c1a4fa88e0170af36ac65a7
6 Na06f80402a604bc68fde7d4f709d7333
7 Naa754d6d140d4af897ccd7accc20db2a
8 Nb66c74d0c2934455a9b1d13ff0f497b6
9 Nd3f12c82526945fa8f49ab96456baf23
10 anzsrc-for:11
11 anzsrc-for:1103
12 schema:author N824d9b86ad614518ba08809b699635af
13 schema:citation sg:pub.10.1038/bjc.1980.273
14 sg:pub.10.1038/bjc.1983.13
15 schema:datePublished 1985-07
16 schema:datePublishedReg 1985-07-01
17 schema:description The levels of serum beta 2 microglobulin, blood urea concentration, serum creatinine, haemoglobin and performance status have been measured in 476 patients in the Medical Research Council's 4th trial for myelomatosis. Levels of serum beta 2 microglobulin were also subsequently measured in 208 patients who achieved a stable "plateau" condition. Serum beta 2 microglobulin levels, uncorrected for serum creatinine, were found to be the single most powerful prognostic variable available at presentation. Multivariate analysis showed that only the addition of haemoglobin levels could improve upon this and the improvement, though statistically significant (P = 0.006), appeared to be of much less clinical value. The prognostic value of serum beta 2 microglobulin at plateau appeared to be equally large for a given difference in value, but the variability between patients was much less at that time. Serum beta 2 microglobulin would appear to be a key measurement for assessing the prognosis and response to treatment in patients with myelomatosis.
18 schema:genre article
19 schema:inLanguage en
20 schema:isAccessibleForFree true
21 schema:isPartOf Ne45ba1a4409a4d5d86340d964244cf75
22 Ne973beecc86a45aa92781097948eb30e
23 sg:journal.1017082
24 schema:keywords Council
25 Medical Research Council
26 Research Council
27 addition
28 analysis
29 beta 2 microglobulin
30 blood urea concentration
31 clinical value
32 concentration
33 conditions
34 creatinine
35 differences
36 features
37 hemoglobin
38 hemoglobin levels
39 improvement
40 key measurements
41 levels
42 measurements
43 microglobulin
44 microglobulin levels
45 multivariate analysis
46 myelomatosis
47 patients
48 performance status
49 plateau
50 powerful prognostic variable
51 presentation
52 presentation features
53 prognosis
54 prognostic value
55 prognostic variables
56 response
57 serum
58 serum beta 2 microglobulin
59 serum creatinine
60 status
61 time
62 treatment
63 trials
64 urea concentration
65 values
66 variability
67 variables
68 schema:name The prognostic value of serum β 2 microglobulin compared with other presentation features in myelomatosis
69 schema:pagination 1-6
70 schema:productId N7c44a613e7a44412b11ed99abe12d97e
71 N8eaa95a4d3f14ed9a2c1a97e2b2f1f0a
72 Nb9d43f3383784b319de1136eaf4da146
73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051235803
74 https://doi.org/10.1038/bjc.1985.140
75 schema:sdDatePublished 2021-12-01T19:06
76 schema:sdLicense https://scigraph.springernature.com/explorer/license/
77 schema:sdPublisher Nd2165399adb04e56aa95a1366d95acaa
78 schema:url https://doi.org/10.1038/bjc.1985.140
79 sgo:license sg:explorer/license/
80 sgo:sdDataset articles
81 rdf:type schema:ScholarlyArticle
82 N2c11cf4bb89d4d92a8a1993670a9fc54 schema:familyName Cuzick
83 schema:givenName J
84 rdf:type schema:Person
85 N2c54e2b4d09c4dbaa615f6f0fc8278a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Prognosis
87 rdf:type schema:DefinedTerm
88 N33d21185bd9d468990091091ed07b621 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Hemoglobins
90 rdf:type schema:DefinedTerm
91 N4ed8fabc836343a39a4521fe04762dca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Time Factors
93 rdf:type schema:DefinedTerm
94 N5342a229386a4af3be88f40c863eb89b rdf:first Nb61b014c3e7744acbecd69f54de054ee
95 rdf:rest N786f228a096540cf8a7a34cd5398ec85
96 N786f228a096540cf8a7a34cd5398ec85 rdf:first Nba0e196da09a473090d3ef74f0ddf119
97 rdf:rest rdf:nil
98 N7bce4d624071402a8b996eb2adf92065 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name beta 2-Microglobulin
100 rdf:type schema:DefinedTerm
101 N7c44a613e7a44412b11ed99abe12d97e schema:name doi
102 schema:value 10.1038/bjc.1985.140
103 rdf:type schema:PropertyValue
104 N824d9b86ad614518ba08809b699635af rdf:first N2c11cf4bb89d4d92a8a1993670a9fc54
105 rdf:rest N5342a229386a4af3be88f40c863eb89b
106 N874585776c1a4fa88e0170af36ac65a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Creatinine
108 rdf:type schema:DefinedTerm
109 N8eaa95a4d3f14ed9a2c1a97e2b2f1f0a schema:name pubmed_id
110 schema:value 3893505
111 rdf:type schema:PropertyValue
112 Na06f80402a604bc68fde7d4f709d7333 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Follow-Up Studies
114 rdf:type schema:DefinedTerm
115 Naa754d6d140d4af897ccd7accc20db2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Multiple Myeloma
117 rdf:type schema:DefinedTerm
118 Nb61b014c3e7744acbecd69f54de054ee schema:familyName Cooper
119 schema:givenName E H
120 rdf:type schema:Person
121 Nb66c74d0c2934455a9b1d13ff0f497b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Humans
123 rdf:type schema:DefinedTerm
124 Nb9d43f3383784b319de1136eaf4da146 schema:name dimensions_id
125 schema:value pub.1051235803
126 rdf:type schema:PropertyValue
127 Nba0e196da09a473090d3ef74f0ddf119 schema:familyName MacLennan
128 schema:givenName I C
129 rdf:type schema:Person
130 Nd2165399adb04e56aa95a1366d95acaa schema:name Springer Nature - SN SciGraph project
131 rdf:type schema:Organization
132 Nd3f12c82526945fa8f49ab96456baf23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Urea
134 rdf:type schema:DefinedTerm
135 Ne45ba1a4409a4d5d86340d964244cf75 schema:volumeNumber 52
136 rdf:type schema:PublicationVolume
137 Ne973beecc86a45aa92781097948eb30e schema:issueNumber 1
138 rdf:type schema:PublicationIssue
139 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
140 schema:name Medical and Health Sciences
141 rdf:type schema:DefinedTerm
142 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
143 schema:name Clinical Sciences
144 rdf:type schema:DefinedTerm
145 sg:journal.1017082 schema:issn 0007-0920
146 1532-1827
147 schema:name British Journal of Cancer
148 schema:publisher Springer Nature
149 rdf:type schema:Periodical
150 sg:pub.10.1038/bjc.1980.273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030704342
151 https://doi.org/10.1038/bjc.1980.273
152 rdf:type schema:CreativeWork
153 sg:pub.10.1038/bjc.1983.13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030167230
154 https://doi.org/10.1038/bjc.1983.13
155 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...